Efficacy & Safety of SM101 in the Treatment of IgA Nephropathy

See also
Status	Clinical Trial	Phase
Completed	`NCT03719443` - First in Human Study to Assess Safety of VIS649 in Healthy Subjects	Phase 1
Enrolling by invitation	`NCT05132621` - The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephropathy.
Recruiting	`NCT05856760` - A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN	Phase 2
Recruiting	`NCT04662723` - Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.	Phase 4
Recruiting	`NCT06291376` - Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)	Phase 3
Completed	`NCT02384317` - Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade	Phase 2
Recruiting	`NCT05732402` - An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases	Phase 1/Phase 2
Active, not recruiting	`NCT05248646` - Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)	Phase 3
Completed	`NCT01838239` - Development of a Metabolic Assessment Tool for Chronic Kidney Disease	N/A
Recruiting	`NCT05852938` - A Study of BION-1301 in Adults With IgA Nephropathy	Phase 3
Recruiting	`NCT05834738` - Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy	Phase 2
Completed	`NCT04287985` - Safety and Efficacy Study of VIS649 for IgA Nephropathy	Phase 2
Recruiting	`NCT05097989` - Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)	Phase 2
Completed	`NCT05200871` - Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)
Terminated	`NCT05162066` - Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)	Phase 2
Active, not recruiting	`NCT04573920` - Atrasentan in Patients With Proteinuric Glomerular Diseases	Phase 2
Recruiting	`NCT04564339` - Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)	Phase 2
Active, not recruiting	`NCT04573478` - Atrasentan in Patients With IgA Nephropathy	Phase 3
Active, not recruiting	`NCT03762850` - A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy	Phase 3
Active, not recruiting	`NCT04663204` - A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy	Phase 2

NCT number	NCT02605525
Study type	Interventional
Source	Takeda
Contact
Status	Withdrawn
Phase	Phase 2
Start date	December 31, 2015
Completion date	November 30, 2016

Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms